文献速递肿瘤 PET/CT

18F-前列腺特异性膜抗原(PSMA)PET/CT示踪剂在高危前列腺癌分期及生化复发再分期中的诊断准确性:综述的综述

Diagnostic Accuracy of 18F-Prostate Specific Membrane Antigen (PSMA) PET/CT Radiotracers in Staging and Restaging of Patients With High-Risk Prostate Cancer or Biochemical Recurrence: An Overview of Reviews.
PubMed 文献 · Semin Nucl Med · 2024-06-21

该综述的综述纳入11篇系统评价,评估18F-PSMA PET/CT在高危前列腺癌分期和生化复发再分期中的诊断准确性。10篇系统评价存在高或不明确偏倚风险,证据确定性为中至极低,但广泛支持18F-PSMA PET/CT在这两类人群中的应用。缺乏剂量、不良事件及与其他影像模态直接比较的数据。

要点

  • 11篇系统评价中10篇存在高或不明确偏倚风险,证据确定性为中至极低。
  • 18F-PSMA PET/CT在高危前列腺癌和生化复发患者中显示高灵敏度、特异度和准确度。
  • 缺乏剂量、不良事件及与其他影像模态直接比较的数据。

核心结论

  • 当前证据基础广泛支持18F-PSMA PET/CT用于高危前列腺癌分期和生化复发再分期。
  • 证据确定性为中至极低,且多数系统评价存在高或不明确偏倚风险。

研究设计与样本

  • 本研究为综述的综述,遵循PRIOR声明和SWiM报告指南进行。
  • 检索数据库和灰色文献至2023年7月18日,纳入11篇系统评价。
  • 使用ROBIS工具评估系统评价偏倚风险,使用GRADE评估证据确定性。

主要发现

  • 11篇系统评价中10篇存在高或不明确偏倚风险。
  • 证据报告了基于患者、淋巴结和病灶的灵敏度、特异度和总体准确度。
  • 中至极低确定性证据表明18F-PSMA PET/CT在高危前列腺癌和生化复发患者中具有高灵敏度、特异度和准确度。
  • 合并中/高危队列结局的证据确定性显著较低且效应估计变异性更大。

局限性

  • 11篇系统评价中10篇存在高或不明确偏倚风险。
  • 缺乏剂量、不良事件及18F-PSMA PET/CT与其他影像模态直接比较的数据。
  • 合并中/高危队列结局的证据确定性显著较低且效应估计变异性更大。
  • 部分结局仍存在证据缺口。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this overview was to consolidate existing evidence syntheses and provide a comprehensive overview of the evidence for 18F-prostate specific membrane antigen (PSMA) PET/CT in the staging of high-risk prostate cancer and restaging after biochemical recurrence. An overview of reviews was performed and reported in line with the preferred reporting items for overview of reviews (PRIOR) statement and synthesis without meta-analysis (SWiM) reporting guidelines. A comprehensive database and grey literature search were conducted up to July 18, 2023. Systematic reviews were assessed using the risk of bias in systematic reviews (ROBIS) tool. The certainty of the evidence was assessed using grading of recommendations, assessment, development and evaluations (GRADE). 11 systematic reviews were identified; 10 were at high or unclear risk of bias. Evidence reported on a per-patient, per-lymph node, and per-lesion basis for sensitivity, specificity and overall accuracy was identified. There was a lack of data on dose, adverse events and evidence directly comparing 18F-PSMA PET/CT to other imaging modalities. Evidence with moderate to very low certainty indicated high sensitivity, specificity and accuracy of 18F-PSMA PET/CT in patients with high-risk prostate cancer and biochemical recurrence. There was considerably lower certainty evidence and greater variability in effect estimates for outcomes for the combined intermediate/high-risk cohort. While evidence gaps remain for some outcomes, and most systematic reviews were at high or unclear risk of bias, the current evidence base is broadly supportive of 18F-PSMA PET/CT imaging in the staging and restaging of patients with high-risk prostate cancer and biochemical recurrence.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Dullea A, O'Sullivan L, O'Brien KK, et al. Diagnostic Accuracy of 18F-Prostate Specific Membrane Antigen (PSMA) PET/CT Radiotracers in Staging and Restaging of Patients With High-Risk Prostate Cancer or Biochemical Recurrence: An Overview of Reviews. Semin Nucl Med. 2024. PMID: 38906759. doi:10.1053/j.semnuclmed.2024.05.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。